155 related articles for article (PubMed ID: 36880147)
1. Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy.
Erlandsson A; Lundholm M; Watz J; Bergh A; Petrova E; Alamdari F; Helleday T; Davidsson S; Andren O; Tarish F
Int J Immunopathol Pharmacol; 2023; 37():3946320231158025. PubMed ID: 36880147
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
Nishiyama T
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
[TBL] [Abstract][Full Text] [Related]
3. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.
Nabid A; Carrier N; Vigneault E; Van Nguyen T; Vavassis P; Brassard MA; Bahoric B; Archambault R; Vincent F; Bettahar R; Wilke D; Souhami L
Eur J Cancer; 2021 Jan; 143():64-74. PubMed ID: 33279855
[TBL] [Abstract][Full Text] [Related]
5. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.
Stoyanova R; Pahlajani NH; Egleston BL; Buyyounouski MK; Chen DY; Horwitz EM; Pollack A
Cancer; 2013 Mar; 119(5):1080-8. PubMed ID: 23096533
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
8. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
Spratt DE; Malone S; Roy S; Grimes S; Eapen L; Morgan SC; Malone J; Craig J; Dess RT; Jackson WC; Hartman HE; Kishan AU; Mehra R; Kaffenberger S; Morgan TM; Reichert ZR; Alumkal JJ; Michalski J; Lee WR; Pisansky TM; Feng FY; Shipley W; Sandler HM; Schipper MJ; Roach M; Sun Y; Lawton CAF
J Clin Oncol; 2021 Jan; 39(2):136-144. PubMed ID: 33275486
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Amit U; Lawrence YR; Weiss I; Symon Z
Radiat Oncol; 2019 Jun; 14(1):99. PubMed ID: 31182119
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis.
Lei JH; Liu LR; Wei Q; Song TR; Yang L; Meng Y; Han P
Asian J Androl; 2016; 18(1):102-7. PubMed ID: 25851657
[TBL] [Abstract][Full Text] [Related]
11. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
[TBL] [Abstract][Full Text] [Related]
13. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
[TBL] [Abstract][Full Text] [Related]
14. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
Mason MD; Parulekar WR; Sydes MR; Brundage M; Kirkbride P; Gospodarowicz M; Cowan R; Kostashuk EC; Anderson J; Swanson G; Parmar MK; Hayter C; Jovic G; Hiltz A; Hetherington J; Sathya J; Barber JB; McKenzie M; El-Sharkawi S; Souhami L; Hardman PD; Chen BE; Warde P
J Clin Oncol; 2015 Jul; 33(19):2143-50. PubMed ID: 25691677
[TBL] [Abstract][Full Text] [Related]
15. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
16. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
Lin CC; Gray PJ; Jemal A; Efstathiou JA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435
[TBL] [Abstract][Full Text] [Related]
18. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
Rijksen BLT; Pos FJ; Hulshof MCCM; Vernooij RWM; Jansen H; van Andel G; Wijsman BP; Somford DM; Busstra MB; van Moorselaar RJA; Kaa CAH; van Leenders GJLH; Hamberg P; van den Berkmortel F; Fütterer JJ; Kiemeney LA; van Oort IM; Aben KKH
Eur Urol Focus; 2021 Mar; 7(2):332-339. PubMed ID: 31748122
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients.
Cerne JZ; McGuire SE; Grant SR; Munsell MF; Lee AK; Kudchadker RJ; Choi SL; Mahmood U; Hoffman KE; Pugh TJ; Frank SJ; Kuban DA
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):346-51. PubMed ID: 23939133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]